WallStreetZenWallStreetZen

NASDAQ: ADAG
Adagene Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ADAG

Based on 3 analysts offering 12 month price targets for Adagene Inc

Min Forecast
$7.00+111.48%
Avg Forecast
$8.67+161.84%
Max Forecast
$10.00+202.11%

Should I buy or sell ADAG stock?

Based on 3 analysts offering ratings for Adagene Inc.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ADAG's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ADAG as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their ADAG stock forecasts and price targets.

ADAG stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-14
lockedlocked$00.00+00.00%2026-09-10
lockedlocked$00.00+00.00%2026-04-06

1 of 1

Forecast return on equity

Is ADAG forecast to generate an efficient return?

Company
N/A
Industry
21.25%
Market
168.71%

Forecast return on assets

Is ADAG forecast to generate an efficient return on assets?

Company
N/A
Industry
23.75%

ADAG earnings per share forecast

What is ADAG's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$0.38
Avg 2 year Forecast
-$0.46
Avg 3 year Forecast
-$0.58

ADAG revenue forecast

What is ADAG's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$5.3M-43.31%
Avg 2 year Forecast
$6.9M-25.65%
Avg 3 year Forecast
$15.6M+67.67%
ADAG's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ADAG revenue growth forecast

How is ADAG forecast to perform vs Biotechnology companies and vs the US market?

Company
15.15%
Industry
32.77%
Market
13.78%
ADAG's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ADAG's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ADAG vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ADAG$3.31$8.67+161.84%Strong Buy
IVVD$0.76$10.00+1,224.50%Strong Buy
KROS$11.19$18.00+60.86%Strong Buy
ZNTL$3.11$9.00+189.39%Strong Buy
AVXL$2.42$24.00+891.74%Strong Buy
View Top Biotech Stocks

Adagene Stock Forecast FAQ

Is Adagene Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: ADAG) stock is to Strong Buy ADAG stock.

Out of 3 analysts, 2 (66.67%) are recommending ADAG as a Strong Buy, 1 (33.33%) are recommending ADAG as a Buy, 0 (0%) are recommending ADAG as a Hold, 0 (0%) are recommending ADAG as a Sell, and 0 (0%) are recommending ADAG as a Strong Sell.

If you're new to stock investing, here's how to buy Adagene stock.

What is ADAG's earnings growth forecast for 2026-2028?

(NASDAQ: ADAG) Adagene's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.22%.

Adagene's earnings in 2026 is -$20,511,005.On average, 9 Wall Street analysts forecast ADAG's earnings for 2026 to be -$32,186,841, with the lowest ADAG earnings forecast at -$42,770,310, and the highest ADAG earnings forecast at -$14,100,102. On average, 9 Wall Street analysts forecast ADAG's earnings for 2027 to be -$38,691,352, with the lowest ADAG earnings forecast at -$49,350,358, and the highest ADAG earnings forecast at -$15,862,615.

In 2028, ADAG is forecast to generate -$48,628,567 in earnings, with the lowest earnings forecast at -$62,510,453 and the highest earnings forecast at -$20,268,897.

What is ADAG's revenue growth forecast for 2026-2028?

(NASDAQ: ADAG) Adagene's forecast annual revenue growth rate of 15.15% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.78%.

Adagene's revenue in 2026 is $9,290,815.On average, 7 Wall Street analysts forecast ADAG's revenue for 2026 to be $442,054,991, with the lowest ADAG revenue forecast at $131,600,954, and the highest ADAG revenue forecast at $1,586,261,502. On average, 6 Wall Street analysts forecast ADAG's revenue for 2027 to be $579,782,775, with the lowest ADAG revenue forecast at $0, and the highest ADAG revenue forecast at $1,586,261,502.

In 2028, ADAG is forecast to generate $1,307,448,766 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $2,451,487,419.

What is ADAG's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ADAG) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 23.75%.

What is ADAG's Price Target?

According to 3 Wall Street analysts that have issued a 1 year ADAG price target, the average ADAG price target is $8.67, with the highest ADAG stock price forecast at $10.00 and the lowest ADAG stock price forecast at $7.00.

On average, Wall Street analysts predict that Adagene's share price could reach $8.67 by Sep 14, 2027. The average Adagene stock price prediction forecasts a potential upside of 161.84% from the current ADAG share price of $3.31.

What is ADAG's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ADAG) Adagene's current Earnings Per Share (EPS) is -$0.38. On average, analysts forecast that ADAG's EPS will be -$0.38 for 2026, with the lowest EPS forecast at -$0.51, and the highest EPS forecast at -$0.17. On average, analysts forecast that ADAG's EPS will be -$0.46 for 2027, with the lowest EPS forecast at -$0.59, and the highest EPS forecast at -$0.19. In 2028, ADAG's EPS is forecast to hit -$0.58 (min: -$0.74, max: -$0.24).

What is ADAG's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ADAG) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.